Management des Prolaktinoms vor, während und nach der Schwangerschaft

Bei Frauen mit unerfülltem Kinderwunsch sollte auch an eine Hyperprolaktinämie gedacht werden. Dieser kann unter anderem ein Prolaktinom zugrunde liegen, ein benignes Hypophysenadenom mit autonomer Prolaktinsekretion. Die Therapie ist häufig unproblematisch, jedoch sind gerade in Zusammenhang mit einer Schwangerschaft einige Besonderheiten zu bedenken.

Abstract

Hyperprolactinemia should actively be investigated as a potential reason of infertility. Underlying prolactinomas may successfully be treated with dopamine agonists. However, patients with micro- or well-circumscribed macroprolactinomas (Knosp 0 or 1) should also be informed about transsphenoidal surgery offering cure in contrast to long-lasting medical therapy. Management prior to and during pregnancy is usually unremarkable but may pose some specific challenges.

Schlüsselwörter

Hyperprolaktinämie - Hypophysenadenom - Prolaktin - Dopaminagonist

Keywords

hyperprolactinemia - pituitary adenoma - prolactin - dopamine agonist

• Literatur

• 1 Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas:The old and the new. Best Pract Res Clin Endocrinol Metabol 2019; 33: 101290
• 2 Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA 2017; 317: 516-524
• 3 Petersenn S. Biochemical diagnosis in prolactinomas: some caveats. Pituitary 2020; 23: 9-15
• 4 Tsur A, Dreyfuss E, Ness-Abramof R. et al. Role of Cannulated Prolactin Test in Evaluation of Hyperprolactinemia – A Retrospective Study. Endocr Pract 2020; 26: 1304-1311
• 5 Varlamov EV, Hinojosa-Amaya JM, Fleseriu M. Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. Pituitary 2020; 23: 16-26
• 6 Burke WT, Penn DL, Castlen JP. et al. Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J Neurosurg 2019; 1-8
• 7 Raverot V, Perrin P, Chanson P. et al. Prolactin immunoassay: does the high-dose hook effect still exist?. Pituitary 2022; 25: 653-657
• 8 Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology 2019; 109: 42-50
• 9 Akinduro OO, Lu VM, Izzo A. et al. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure. World Neurosurg 2019; 129: e686-e694
• 10 De Sousa SMC, Baranoff J, Rushworth RL. et al. Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors. J Clin Endocrinol Metab 2020; 105: dgz076105
• 11 Stiles CE, Lloyd G, Bhattacharyya S. et al. Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints. J Clin Endocrinol Metab 2021; 106: e711-e720
• 12 Dekkers OM, Lagro J, Burman P. et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 43-51
• 13 Hu J, Zheng X, Zhang W. et al. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 2015; 18: 745-751
• 14 Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F. et al. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2020; 105: e32-e41
• 15 Giese S, Nasi-Kordhishti I, Honegger J. Outcomes of Transsphenoidal Microsurgery for Prolactinomas – A Contemporary Series of 162 Cases. Exp Clin Endocrinol Diabetes 2021; 129: 163-171
• 16 Gillam MP, Molitch ME, Lombardi G. et al. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534
• 17 Petersenn S, Christ-Crain M, Droste M. et al. Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment. Geburtshilfe Frauenheilkd 2019; 79: 365-374
• 18 Huang W, Molitch ME. Pituitary Tumors in Pregnancy. Endocrinol Metab Clin North Am 2019; 48: 569-581
• 19 Sant’ Anna BG, Musolino NRC, Gadelha MR. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary 2020; 23: 120-128
• 20 Luger A, Broersen LHA, Biermasz NR. et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol 2021; 185: G1-G33
• 21 Glezer A, Bronstein MD. Prolactinomas: how to handle prior to and during pregnancy?. Minerva Endocrinol 2018; 43: 423-429